The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial

We examined the effects of a dihydropyridine calcium channel blocker nilvadipine with anti-inflammatory properties on cognition and cerebrospinal fluid (CSF) biomarkers by baseline Alzheimer's disease (AD) severity. Exploratory analyses were performed on the dataset (n = 497) of a phase III ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdullah, Laila, Crawford, Fiona, Tsolaki, Magda, Börjesson-Hanson, Anne, Olde Rikkert, Marcel, Pasquier, Florence, Wallin, Anders, Kennelly, Sean, Ait-Ghezala, Ghania, Paris, Daniel, Hendrix, Suzanne, Blennow, Kaj, Lawlor, Brian, Mullan, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067750/
https://www.ncbi.nlm.nih.gov/pubmed/32210906
http://dx.doi.org/10.3389/fneur.2020.00149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067750/
https://www.ncbi.nlm.nih.gov/pubmed/32210906
http://dx.doi.org/10.3389/fneur.2020.00149

Ejemplares similares